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Recurrence of mixed 
cryoglobulinaemia vasculitis 
following influenza vaccination 
despite clearance of hepatitis C 
virus infection 
Sirs,
Mixed cryoglobulinaemia vasculitis (MCV) 
is a serious autoimmune/lymphoprolifera-
tive disease triggered by hepatitis C virus 
(HCV) in most cases. It is characterised by 
the presence of circulating cryoprecipita-
ble immune complexes consisting of poly-
clonal IgGs and mono- or polyclonal IgMs 
with rheumatoid factor activity. The clinical 
manifestations of MCV are secondary to 
systemic vasculitis of the small/medium ves-
sels and range from purpura, arthralgia, and 
asthenia to severe involvement of the pe-
ripheral nervous system and the kidneys (1). 
Over the last three years, the availability of 
highly efficacious and well-tolerated direct-
acting antivirals (DAAs) used in interferon 
(IFN)-free regimens has revolutionised the 
management of HCV infection and opened 
up new opportunities for the treatment of 
HCV-associated MCV (HCV-MCV) (2-4). 
Although viral clearance has been associated 
with remission of vasculitis (5), long-term 
outcome of MCV patients who have eradi-
cated HCV remains unclear (6-8). Here, we 
report a case of recurrence of HCV-MCV 
following influenza vaccination despite viral 
clearance after treatment with DAAs. 
A 54-year-old man with a history of HCV-
MCV with extensive purpura, severe ne-
phrotic syndrome and stage 3 chronic kid-
ney disease was referred to us for treatment 
with DAAs. He had HCV genotype 2 infec-
tion and mild liver fibrosis. Furthermore, 
he was null-responder to prior therapy with 
pegIFN/ribavirin and had shown transient 
clinical response to sequential treatment 
with high-dose pulse glucocorticoids and 
rituximab. Laboratory analysis showed 
HCV RNA of 6 x 106 IU/mL, cryocrit and 
C4 levels of 9% and 0.01 g/L, respectively, 
serum creatinine of 2 mg/dL, and proteinu-
ria of 3.9 g/24 hours. On physical examina-
tion, there was palpable purpura of the low-
er limbs. Treatment with sofosbuvir plus 
ribavirin for 12 weeks was therefore start-
ed, with dramatic reduction in HCV RNA, 
rapid decrease in the cryocrit level and 
progressive improvement in renal function. 
Purpura disappeared. At post-treatment 
week 12, HCV RNA and serum cryoglobu-
lins were undetectable, creatinine was 1.4 
mg/dL, and proteinuria 0.4 g/24 hours (Fig. 
1). A sustained virological response (SVR) 
and a complete clinical response were 
therefore achieved. Two months later, the 
patient underwent seasonal influenza vac-
cination, 10 days after which he developed 
upper and lower limb purpura. Recurrence 
of vasculitis was associated with reappear-
ance of serum cryoglobulins (cryocrit 8%) 
and deterioration of renal function (serum 
creatinine 2.3 mg/dL, protenuria 1.1 g/24 
hours). HCV RNA was confirmed nega-
tive. We closely monitored the patient, who 
showed a spontaneous, gradual resolution 
of purpura. The kidney function returned 
to the pre-vaccination levels within two 
months. The cryocrit level decreased to 1%, 
but remained positive (Fig. 1).
MCV is the most frequent extrahepatic 
manifestation of chronic HCV infection 
(1). Treatment-induced HCV clearance has 
been associated with the persistent resolu-
tion or at least an improvement of the clini-
cal and laboratory manifestations of HCV-
MCV (2-6), although there is increasing 
evidence of persistent MCV despite virus 
eradication (7, 8). The latter finding sup-
ports the hypothesis that some cryoglobu-
lin-producing B-cell clones can proliferate 
independently of the viral trigger, thereby 
perpetuating vasculitis (7). The same path-
ogenic mechanism may explain the recur-
rence of MCV after influenza vaccination 
in our patient.
To the best of our knowledge, this is the 
first reported case of vaccine-induced re-
currence of HCV-MCV despite the achieve-
ment of an SVR to antiviral therapy; only 
new-onset MCV following influenza or 
hepatitis B vaccinations in non-HCV-in-
fected subjects was occasionally observed 
previously (9,10). In the era of IFN-free 
DAA therapy, long-term effects of HCV 
eradication in MCV patients remain there-
fore to be established. New antigenic stim-
Fig. 1. Changes in the levels of plasma HCV RNA, cryocrit (top panel), serum creatinine and proteinuria (bottom 
panel) during antiviral therapy with sofosbuvir plus ribavirin and after influenza vaccination. Abbreviations: SOF: 
sofosbuvir; RBV: ribavirin.
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uli, including vaccinations, may reactivate 
latent cryoglobulin-producing B-cell clones 
in patients who cleared HCV-infection, 
causing recurrence of vasculitis. However, 
such recurrences seem self-limited and 
should not prevent physicians from vacci-
nating MCV patients when appropriate.
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